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Complications and dosing frequency of 5% 
imiquimod for genital warts in a young 
man 
SEBASTIAN A. HOAK, Wayne State University School of Medicine, gm2861@wayne.edu 
 
ABSTRACT A clinical decision report using: 
Fife KH, Ferenczy A, Douglas JM Jr, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a 
week, once daily, twice daily, or three times a day. Sex Transm Dis. 2001;28(4):226-231. https://doi.org/10.1097/00007435-
200104000-00007  
for a patient with genital warts and an unstable social support network. 
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Clinical-Social Context 
William Brown (pseudonym) is a 27-year-old man, who presented to the clinic for follow-up regarding adverse 
reactions to 5% imiquimod prescribed for peri-anal and penile condyloma acuminata. His reactions included flu-
like symptoms, severe itching, ulceration, and burning, all of which began on the second week of treatment. These 
reactions led to a cessation of treatment for one week (3 doses), followed by two doses in one day, then daily 
application of imiquimod to “make up for missed times.” On resumption of imiquimod, he felt worsening burning 
and itching prompting his return visit. Mr. Brown has no significant past medical history or other sexually 
transmitted infections (STIs), which were tested for five weeks previously This testing included HIV, syphilis, 
gonorrhea and chlamydia. The patient has had a total of four sexual partners, only one in the past year, all of 
which were male. He has always used barrier protection during intercourse except with his current partner who 
has no symptoms. On initial presentation, he had 3 peri-anal condylomas the largest measuring 10x7x3mm and 
one 3x2x2mm penile papule on his circumcised shaft. These were initially found by his partner and have been 
causing a great deal of distress for the patient as he had just stopped using protection due to being in a committed 
relationship. He cohabitates with his partner and his income was affected by the global pandemic.  Mr. Brown is 
concerned that his partner will blame him for transmitting genital warts and that not having the condylomas 
treated will result in the end of his relationship and thus a loss of housing. Loss of affordable housing was 
particularly threatening because upon openly identifying as LGBT his family had “disowned” him. Consequently he 
has no social or financial support from his family and is concerned with the cost of other therapies. This stress led 
him to resume smoking 5 cigarettes a day after having quit for three years. It seemed as though his initial medical 
presentation was spiraling into a situation that could have serious long term adverse outcomes for his health. 
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Clinical Question 
Can 5% imiquimod be applied more frequently than the prescribed three times weekly to increase genital wart clearance in a gay 
man? 
Research Article 
Fife KH, Ferenczy A, Douglas JM Jr, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a 
week, once daily, twice daily, or three times a day. Sex Transm Dis. 2001;28(4):226-231. https://doi.org/10.1097/00007435-
200104000-00007 1 
Description of Related Literature 
A search for original research was done on PubMed using the keywords “imiquimod”, “condyloma”, and “men”. The keyword “men” 
was included as males are known to have a difference in response to imiquimod treatment.2 That search yielded 34 results. Thirty-
one of those studies were rejected as they were not relevant to the clinical question for the following reasons; the most common 
reason for rejection was the study compared imiquimod to other treatments3-15, 5% imiquimod formulation was not being studied16-
18, studied malignancies associated with HPV and not genital warts19-23, studied specialty populations i.e. immunocompromised (due 
to HIV) or the persons’ genitalia was altered24-26, imiquimod being used as an adjunct post-procedural removal27-28, did not evaluate 
frequency29-31, a study that was case reports32, or was a review of current guidelines33. 
Of the remaining three articles one was a meta-analysis.34 This study’s reference list (30 articles) and cited by list (8 articles) were 
reviewed for other relevant studies. However, this only led to previously reviewed or irrelevant articles for the various reasons listed 
above. A study identified in the meta-analysis, also tested dosing frequency but focused solely on women.35 This left 2 highly 
relevant studies, both of which were found by the above search and were evaluated in the meta-analysis.1,36 Both happened to be 
clinical trials that tested frequency of 5% imiquimod on genital warts. Gollnick et al. was a phase II, dose escalation, open-label, 
multicenter European study aimed at assessing safety.36 However, it was not randomized, specified that the men must have a 
foreskin, and included HIV+ men. Mr. Brown would not have qualified for this study as he does not have enough wart burden on his 
penis and has no foreskin. Thus, the most suited study for critical appraisal was written by Fife et al.1 The study closely approximated 
Mr. Brown’s clinical question by studying 4 different dosing frequencies of 5% imiquimod, 3 of which were greater than his 
prescribed dose. The area in question meets the criteria for SORT class B strength of recommendation given its consistent yet 
limited-quality patient-oriented evidence.37 
Critical Appraisal 
This article describes a randomized control trial (RCT) that recruited participants from 9 clinical sites across the USA and Canada. The 
Strength of Recommendation Taxonomy (SORT)37 classifies this study as having a level 2 study quality. It falls short of a level 1 
ranking solely due to a suboptimal patient follow up rate below 80%. To be considered for this trial, men were required to have 2-50 
condyloma acuminatum, confirmed by biopsy. Participants couldn’t have previously received imiquimod or had any other treatment 
4 weeks prior to the study to constrain confounding variables. Predominantly HIV negative white males with an average age of 32 
were studied, similar to the patient being described in this report making the study highly applicable. Upon enrollment patients 
were consecutively assigned a study number, which was placed on a randomization table, assigning each of the 110 patients to one 
of four treatment regimens. Regimens include applying 5% imiquimod either once (n=29), twice (n=29), three times daily (n=26) or 
the standard of care which is three times per week (n=26).  
The selection criteria and successful randomization limit selection bias potential while providing a representative sample. Neither 
blinding nor placebos were utilized, likely due to ethical issues of post-marketing research with an already established drug efficacy, 
however patients were told about the doubt of the optimal regimen. The research being done after drug approval removes the 
possibility of publication bias. Additionally, the use of objective measures mitigates potential performance bias that could arise from 
a lack of blinding. Thus, no particular group appears to be favored. Measures were assessed at set intervals and included measuring 
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and photographing lesions and skin reactions such as redness, swelling, vesicles, erosions etc. Routine blood and urine tests were 
drawn to measure drugs levels, inflammation, and HPV antibodies.  
Of the 110 participants, only 75 completed the study. 24 individuals were lost to follow-up, making it the most common attrition 
factor. 4 others withdrew due to adverse reactions to the treatment, the majority of which were in the most frequent dosing study 
arm. The low follow up rate is the reasoning behind this RCT receiving SORT level 2.37 This loss to follow-up is concerning as it leads 
to a large potential for bias in the results, which is not addressed in this study. It is unknown if the loss is due to adverse reactions, 
wart clearance or patient factors, such as patient embarrassment. 
The primary outcome of the trial revealed that only 35 (31.8%) men showed complete wart clearance via intent to treat analysis. The 
percent clearance was different between treatment groups: 3x weekly (35%), daily (28%), twice daily (24%), thrice daily (27%), 
however was not statistically significant likely due to the small sample size. The clearance rates are likely artificially reduced due to 
the analysis including the 32% lost being treated as failures. Nonetheless, the median percent reduction of wart area was over 90% 
in all groups with the greatest reduction being seen in the 3x weekly frequency arm. Again, this was not statistically significant. Of 
note, 39 participants developed new lesions during the 16-week trial and 15 men cleared these new lesions. Interestingly, though 
more frequent dosing decreased the incidence of new lesions, a decrease in clearance was associated with increased frequency. This 
unexpected finding, although not statistically significant, was hypothesized to be due either to intermittent drug free periods from 
adverse medication reactions in more frequent dosing schedules or cytokine hyperresponsiveness due to repeated stimulation.  
Safety was assessed by reported adverse events (erythema, vesicles, ulcerations, excoriations, pain and systemic symptoms). 
Fortunately, these symptoms do not overlap with symptoms of condyloma, alleviating ascertainment bias. These adverse reactions 
were assessed by clinicians at each visit by comparing photographs, which occurred after weekly for the first month followed by 
every other week for the following 3 months. Additionally, patients kept diaries of self-reported events and compliance that were 
reviewed at each visit.  There was a non-significant increase in the number of adverse events with increasing frequency of 
imiquimod, but a significant increase in the severity of the events. The 58.3% rate of adverse events in the standard treatment 
compared to 76.9% in the thrice daily. The number needed to harm (NNH), when compared to the treatment standard of 3x per 
week, is a key statistic not included in this study; daily (NNH=26.3), twice daily (NNH=6.33), thrice daily (NNH=5.38). Unfortunately, 
this statistic does not reflect the increased severity of the reactions. Adverse reaction severity also led to an associated increase in 
rest periods or a period of missing doses to allow for reactions to subside. Of those in the 3x weekly group, 9 took a rest period, 
compared to 18 in the daily group, 24 in the twice daily, and 20 in the thrice daily group. Oddly, systemic adverse events were not 
associated with dosing frequency. Upon investigation of adverse reactions, no meaningful abnormalities in chemistry or hematologic 
values were noted, nor was imiquimod detected in patients’ serum.  
Generally, the study was able to answer that optimal dosing frequency is three times weekly, however it was not statistically 
significant. This limitation is likely due to the small sample size as well as the low follow up. Of greatest concern is the potential for 
source bias, as funding for this study was provided by 3M Pharmaceuticals, the producer of Aldara-brand imiquimod. Whether this 
affected the study is unknown. 
Clinical Application 
Mr. Brown would have met criteria to be screened for inclusion of the study by Fife et al. as he is a male with more 
than 2 condylomas with an area greater than 30mm2, supporting strong external validity. Regarding whether 5% 
imiquimod can be applied more frequently than 3 times weekly to accelerate wart clearance, the study indicated 
not. In fact, increasing dosing is associated with an increase in the number and severity of reaction as well as 
increasing the number of rest periods. This study can be applied to Mr. Brown’s case as it showed a range of 
different application frequencies as well as the effects of this frequencies, mirroring Mr. Brown’s situation. While 
this information was not statistically significant it has been reproduced in other non-randomized trials and also 
showed a nonsignificant decline in efficacy with increased frequency.9,36 Thus, it was recommended that he use the 
imiquimod as prescribed.  
To address the Mr. Brown’s concerns regarding limited funds, imiquimod was recommended. Imiquimod is the 
cheapest patient-applied option according to GoodRX, for peri-anal warts. Additionally, the increase in stress, both 
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financial and personal, has led to his resumption of smoking, which can be expected based on previous studies.38 It 
has been shown that this elevated stress increases disease burden of HPV39, and that the resultant smoking 
decreases wart clearance in men.40 These factors were discussed with the patient and a referral was placed to a 
mental health provider to improve coping skills. Mr. Brown acknowledged his need to quit smoking as well as his 
understanding that imiquimod is best applied 3x weekly for best overall results. While not statistically significant, 
there were no harms in providing this information as no difference were seen in clearance with differing 
frequencies. There is strong internal validity to this study as the results match the conclusion. The possible benefits 
are a reduction in the number of adverse reactions and an almost certain decrease in the severity of his reactions, 
which will likely decrease his stress surrounding the matter. 
New Knowledge Related to Clinical Decision Science 
Although there are no randomized clinical trials large enough to provide statistically significant evidence on the frequency of 5% 
imiquimod dosing, this study provides notable associations surrounding the negatives of his increased dosing frequency secondary 
to an adverse reaction. The increased reaction severity and possible decrease in efficacy associated with increased dosing were 
discussed with Mr. Brown as well as the limitation of this study. Information such as this is essential to many patients, especially in 
times of stress when a disease could alter lives in ways clinicians cannot initially foresee.  
The lack of information and heightened stress led to behavior that might have worsened the patient’s medical response, which in 
turn created an adverse reaction, further increasing stress. This stress, compounded on existing stress provoked Mr. Brown to 
resume smoking, entailing a cadre of associated diseases.  While information can help the patient, it is necessary that providers 
review articles thoroughly to utilize the most appropriate study and interpret the information as the analysis done can alter the 
conclusion taken from the data. Always keep in mind the various biases that can affect one’s results and interpretation.  
Ultimately, Mr. Brown needed advice on the dosing of imiquimod, which was available in the clinical research literature. But, this 
evidence is nested within a vast set of other needs, most of them social and emotional. Clinical Decision Science requires that the 
clinical evidence harmonize with other aspects of this therapeutic relationship. Because of the non-supportive nature of his 
relationships with his family and domestic partner, it is even more important that the doctor patient relationship model respect and 
care. A simple way to do that is to ask for a short interval follow up visit to re-assess the response to therapy and verify success of 
referral advice in a health system struggling with a pandemic. 
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